Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

32.02USD
24 Feb 2017
Change (% chg)

-- (--)
Prev Close
$32.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
649,419
52-wk High
$63.73
52-wk Low
$8.00

SRPT.OQ

Chart for SRPT.OQ

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in... (more)

Overall

Beta: 1.76
Market Cap(Mil.): $1,747.98
Shares Outstanding(Mil.): 54.59
Dividend: --
Yield (%): --

Financials

  SRPT.OQ Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -5.27 -- --
ROI: -85.52 -3.35 12.96
ROE: -91.56 5.80 14.11

BRIEF-Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln

* Sarepta Therapeutics agrees to sale of priority review voucher for $125m

Feb 21 2017

BRIEF-Sarepta Therapeutics enters into license agreement with nationwide children's hospital

* Sarepta Therapeutics enters into license agreement with nationwide children's hospital for GALGT2 gene therapy program Source text for Eikon: Further company coverage:

Jan 10 2017

Trump presidency could prove a salve for pharma merger deals

NEW YORK Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A. | Video

Nov 11 2016

RPT-Trump presidency could prove a salve for pharma merger deals

NEW YORK, Nov 11 Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A.

Nov 11 2016

Trump presidency could prove a salve for pharma merger deals

NEW YORK, Nov 11 Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A.

Nov 11 2016

BRIEF-Sarepta Therapeutics Q3 loss per share $1.18

* Sarepta Therapeutics announces third quarter 2016 financial results and recent corporate developments

Oct 27 2016

Anthem won't cover first FDA-approved Duchenne drug

Oct 7 Health insurer Anthem Inc said it would not cover the first U.S. Food and Drug Administration-approved Duchenne muscular dystrophy (DMD) drug, developed by Sarepta Therapeutics Inc, calling it "investigational and not medically necessary".

Oct 07 2016

Sarepta partners with UK's Summit on Duchenne drugs

Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.

Oct 04 2016

UPDATE 3-Sarepta partners with UK's Summit on Duchenne drugs

Oct 4 Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.

Oct 04 2016

BRIEF-Summit's agreement with Sarepta also contains a standstill provision

* Collaboration agreement with Sarepta also contains a standstill provision - SEC filing

Oct 04 2016

More From Around the Web

Earnings vs. Estimates